- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03197493
Extension, Carbidopa-levodopa in Neovascular AMD
December 10, 2020 updated by: Snyder, Robert W., M.D., Ph.D., P.C.
Extension of Protocol 002, Carbidopa-levodopa in Neovascular Extension of Protocol 002, Carbidopa-levodopa in Neovascular AMD
This protocol is an extension of protocol 0002, Proof of Concept and Dose Ranging Study of carbidopa-levodopa in Neovascular AMD. that is a 3 month study of escalating doses of carbidopa-levodopa in neovascular AMD.
This trial is a 9 month extension for patients who successfully complete protocol 0002 and wish to continue carbidopa-levodopa therapy.
It will use the two higher dose regimens of protocol 0002.
these will be assigned according to how well the higher dose was tolerated in protocol 0002.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This extension will employ the same medications, measurements, guidelines for anti-VEGF injections and safeguards as in protocol 0002.
In combination with protocol 0002, it will provide a total of 12 months of therapy with carbidopa-levodopa.
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85712
- Robert W Snyder, MD, PhD, PC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Completion of Protocol 002.
- A diagnosis of AMd with choroidal neovascularization (CNV) in 1 eye.
- Normal or Dry AMD of any grade in the second eye.
- Age 50-85 years.
- Willingness to maintain AREDS vitamin Supplements throughout the study, or remain off of these supplements for the duration of the study, if not taking them prior to the study.
- Informed consent at visit 1, which is also Visit 5 of study 002.
Exclusion criteria:
- Any current use of L-DOPA containing medication or dopamine agonist medication, or any planned use of any of these agents, except for study medication, during the study;
- Concurrent use of monoamine oxidase (MAO) inhibitors;
- Any eye condition, disease, or history of trauma in either eye, which can impair vision, except cataract or cataract surgery;
- BCVA worse than 20/60 in the better eye;
- Wet AMD in the second eye;
- Neurologic conditions which can impair vision;
- Parkinson's Disease;
- Significant orthostatic hypotension, defined as a drop in systolic blood pressure, immediately upon changing from the supine to standing position, of >19 mmHg, or a symptomatic drop in systolic blood pressure, immediately upon changing from the supine to standing position;
- Significant ECG abnormalities, as judged by the Investigator;
- Estimated glomerular filtration rate (eGFR) <20 ml/min;
- Liver enzymes >3 X the upper limit of normal;
- HbA1C >9.0;
- Any other significant lab abnormalities, as judged by the Investigator.
- Women of childbearing potential;
- Known retinal hemorrhage;
- Subjects who are not fluent in English.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Dose
carbidopa-levodopa 25-100 mg 2 tablets TID
|
High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
|
Experimental: Intermediate Dose
carbidopa-levodopa 25-100 mg 1 tablet TID
|
High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Corrected Visual Acuity by ETDRS visual scale testing
Time Frame: From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study (visit 10), a maximum of 9 months.
|
Currently refracted, normal light, lines and letters read on the ETDRS chart
|
From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study (visit 10), a maximum of 9 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events experienced by participants during the study
Time Frame: Monthly for 9 months
|
Adverse events elicited by nonspecific questioning
|
Monthly for 9 months
|
By OCT, central retinal thickness, in the eye with neovascular AMD
Time Frame: From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study (visit 10), a maximum of 9 months.
|
Central retinal thickness by OCT
|
From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study (visit 10), a maximum of 9 months.
|
By OCT, drusen volume in the eye without neovascular AMD
Time Frame: From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study, (visit 10), a maximum of 9 months.
|
drusen volume
|
From the start of the study (Visit 1) to the last completed visit, whether due to patient withdrawal, patient death or the completion of the last visit of the study, (visit 10), a maximum of 9 months.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2017
Primary Completion (Actual)
July 9, 2020
Study Completion (Actual)
July 9, 2020
Study Registration Dates
First Submitted
June 19, 2017
First Submitted That Met QC Criteria
June 21, 2017
First Posted (Actual)
June 23, 2017
Study Record Updates
Last Update Posted (Actual)
December 11, 2020
Last Update Submitted That Met QC Criteria
December 10, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Immunologic Factors
- Dopamine Agonists
- Dopamine Agents
- Adjuvants, Immunologic
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Aromatic Amino Acid Decarboxylase Inhibitors
- Levodopa
- Carbidopa
- Carbidopa, levodopa drug combination
Other Study ID Numbers
- 0003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retina
-
The Second People's Hospital of FoshanRecruiting
-
Masaryk Hospital Usti nad LabemCompleted
-
The Second People's Hospital of FoshanNot yet recruiting
-
Shaare Zedek Medical CenterUnknownRetina, Choroid, Sclera
-
Sun Yat-sen UniversityCompletedNormal Eyes | Peripheral RetinaChina
-
University of OxfordCompletedRetina; ChangeUnited Kingdom
-
Zilia Inc.CHU de Quebec-Universite LavalTerminatedRetinal Vascular | RetinaCanada
-
University Hospital TuebingenCompletedAdherence | Retina; LesionGermany
-
Centre Hospitalier Universitaire DijonUnknownPatients Undergoing Retina/Vitreous SurgeryFrance
Clinical Trials on carbidopa-levodopa 25-100 mg
-
Snyder, Robert W., M.D., Ph.D., P.C.WithdrawnAge-related Macular DegenerationUnited States
-
Desitin Arzneimittel GmbHCompleted
-
University of MichiganNational Institute on Aging (NIA)RecruitingParkinsonian Signs in Older PersonsUnited States
-
Bial - Portela C S.A.CompletedParkinson DiseaseCanada
-
Snyder, Robert W., M.D., Ph.D., P.C.Completed
-
Snyder, Robert W., M.D., Ph.D., P.C.Completed
-
Bial - Portela C S.A.CompletedParkinson's Disease (PD)France
-
NovartisCompletedParkinson's DiseaseUnited States, Canada, Czechia, Israel, Italy, Poland, Portugal, Turkey
-
Bial - Portela C S.A.Completed
-
IRCCS San Raffaele RomaSynAgile CorporationCompleted